Patents by Inventor Patrick van Berkel

Patrick van Berkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11866514
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: January 9, 2024
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Patent number: 11795214
    Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 24, 2023
    Assignee: GENMAB A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald Van Den Bremer
  • Publication number: 20230227495
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: September 7, 2022
    Publication date: July 20, 2023
    Inventors: Michael GRAMER, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Amout F. Gerritsen
  • Publication number: 20220396629
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 15, 2022
    Inventors: Paul PARREN, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • Patent number: 11492371
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: November 8, 2022
    Assignee: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout F. Gerritsen
  • Publication number: 20220323582
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: October 15, 2021
    Publication date: October 13, 2022
    Inventors: Sandra VERPLOEGEN, Marije OVERDIJK, Riemke VAN DIJKHUIZEN, Willem Karel BLEEKER, Patrick VAN BERKEL, Paul PARREN, Steen LISBY
  • Publication number: 20220177585
    Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
    Type: Application
    Filed: June 16, 2021
    Publication date: June 9, 2022
    Inventors: Catharina Emanuele GERARDA HAVENITH, Tom VINK, Patrick VAN BERKEL, Paul PARREN
  • Publication number: 20210395384
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: March 10, 2021
    Publication date: December 23, 2021
    Inventors: David SATJIN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • Publication number: 20210324105
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: January 14, 2021
    Publication date: October 21, 2021
    Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
  • Publication number: 20200262932
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
    Type: Application
    Filed: January 30, 2020
    Publication date: August 20, 2020
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Ewald T. J. VAN DEN BREMER, Joost J. NEIJSSEN, Patrick VAN BERKEL, Bart DE GOEIJ, Tom VINK, Jan VAN DE WINKEL, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20200131253
    Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
    Type: Application
    Filed: April 30, 2019
    Publication date: April 30, 2020
    Inventors: Paul PARREN, Patrick VAN BERKEL, Ewald VAN DEN BREMER
  • Patent number: 10597464
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: March 24, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Publication number: 20200048304
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: May 30, 2019
    Publication date: February 13, 2020
    Inventors: Michael GRAMER, Amitava KUNDU, Ewald T. J. VAN DEN BREMER, Muriel VAN KAMPEN, Patrick PRIEM, Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Janine SCHUURMAN, Paul PARREN, Patrick VAN BERKEL, Werner L. VOS, Arnout F. GERRITSEN
  • Publication number: 20190315880
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 17, 2019
    Inventors: David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • Patent number: 10351629
    Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 16, 2019
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
  • Patent number: 10344050
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 9, 2019
    Assignee: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
  • Patent number: 10323081
    Abstract: Provided are antibody variants having decreased or increased ability to mediate complement-dependent cytotoxicity (CDC) due to the presence or absence of C-terminal lysines of their heavy chains. Also provided are methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of such antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: June 18, 2019
    Assignee: GENMAG A/S
    Inventors: Paul Parren, Patrick Van Berkel, Ewald T. J. Van Den Bremer
  • Publication number: 20190169298
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: November 7, 2018
    Publication date: June 6, 2019
    Inventors: Paul PARREN, Janine SCHUURMAN, Tom VINK, Willem Karel BLEEKER, Jan VAN DE WINKEL, Patrick VAN BERKEL, Frank BEURSKENS
  • Patent number: 10155816
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: December 18, 2018
    Assignee: GENMAB A/S
    Inventors: Paul Parren, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • Publication number: 20170369590
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN